Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
April 15, 2021 10:31 ET | Biomerica, Inc.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including...
$423.3 Million Worldwide Irritable Bowel Syndrome with Diarrhea Industry to 2028 - Increasing Demand for Spicy Food Will Boost the Drug Market Growth in North America
February 22, 2021 07:23 ET | Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results
September 01, 2020 08:19 ET | Biomerica, Inc.
Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
June 29, 2020 21:39 ET | Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
February 26, 2020 16:41 ET | Biomerica, Inc.
IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of...
Biomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter
January 15, 2020 08:19 ET | Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the...
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
January 07, 2020 08:19 ET | Biomerica, Inc.
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)InFoods® Diagnostic...
Biomerica Announces Fiscal Year End 2019 Financial Results
August 30, 2019 08:30 ET | Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
ARC logo.png
Irritable Bowel Syndrome Treatment Market Size Worth Around US$ 3.4 Bn by 2026
July 16, 2019 14:00 ET | Acumen Research and Consulting
Acumen Research and Consulting, Recently Published Report titled “Irritable Bowel Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2019-2026”. LOS ANGELES, July 16, 2019 (GLOBE...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
May 29, 2019 07:30 ET | Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...